A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Tesofensine (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors NeuroSearch
- 12 Apr 2017 According to a Saniona media release, this trial is expected to be completed within two years from initiation.
- 12 Apr 2017 Status changed from planning to not yet recruiting, according to a Saniona media release.
- 12 Apr 2017 According to a Saniona media release, the Mexican regulatory authority, Cofepris, has approved this study.